Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Announces First-Quarter 2022 Dividend

11/30/2021 | 02:49pm EST

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.69 per share of the company’s common stock for the first quarter of 2022. Payment will be made on Jan. 7, 2022 to shareholders of record at the close of business on Dec. 15, 2021.

About Merck

For over 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).


ę Business Wire 2021
All news about MERCK & CO., INC.
01/14Pfizer Reportedly Seeks Japan Approval for COVID-19 Pill
MT
01/14Merck's COVID-19 Pill Molnupiravir Gets Emergency Approval in Indonesia
MT
01/12I-Mab Doses First Phase 2 Clinical Trial of Efineptakin Alfa, Keyrtruda Combination in ..
MT
01/12IMV Doses First Patient in Study for Lymphoma Treatment
DJ
01/11Aligos Therapeutics Shares Rise 6% on Merck Collaboration Agreement
DJ
01/11GLOBAL MARKETS LIVE : Airbus, Nokia, Pandora, Darktrace, Amazon...
01/11Today on Wall Street: All eyes on Powell
01/11Aligos Therapeutics, Merck Expand Collaboration in Nonalcoholic Steatohepatitis
MT
01/11Merck's KEYTRUDA (pembrolizumab) Showed Statistically Significant Improvement in Diseas..
AQ
01/11Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy in Combi..
AQ
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 687 M - -
Net income 2021 11 938 M - -
Net Debt 2021 17 019 M - -
P/E ratio 2021 17,4x
Yield 2021 3,21%
Capitalization 206 B 206 B -
EV / Sales 2021 4,57x
EV / Sales 2022 3,85x
Nbr of Employees 73 500
Free-Float -
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 81,38 $
Average target price 92,27 $
Spread / Average Target 13,4%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.6.18%205 561
JOHNSON & JOHNSON-1.89%441 855
ROCHE HOLDING AG-3.72%323 901
PFIZER, INC.-6.94%308 427
ABBVIE INC.0.35%240 202
ELI LILLY AND COMPANY-11.62%221 317